Compare Yum China Holdings Inc (YUMC) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Yum China Holdings Inc vs Zoetis Inc — how do they compare? Yum China Holdings Inc trades at $42.88 (market cap $14.11B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 2.1× Yum China Holdings Inc's market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Yum China Holdings Inc for 77 Days and Zoetis Inc for 70 Days on average.
| YUMC | ZTS | |
|---|---|---|
Market Cap | $14.11B | $30.20B |
Volume | 2,350,650 | 6,175,327 |
Sector | Consumer Cyclical | Health |
52-Week High | $57.95 | $147.53 |
52-Week Low | $39.98 | $69.09 |
Typical Hold Time | 77 Days | 70 Days |
Enterprise Value | $15.02B | $37.76B |
Dividend Yield | 2.78% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
YUMC trades at $42.92, up 5.58% today, with strong analyst support (73.68% buy ratings) but technical indicators show bearish momentum. The company demonstrates solid fundamentals with consistent revenue growth from $9.6B in 2022 to $11.8B in 2025, and net income improving to $929M. Recent strategic moves include the $1.2B acquisition of Pizza Hut China brand ownership and expansion of Pizza Hut Burger Bars to 300 locations.
YUMC presents a value opportunity with reasonable valuation (P/E 15.3, P/S 1.2) and strong profitability (ROE 17.5%), though technical weakness and China economic exposure pose near-term risks. The stock's 25.6% analyst upside potential and consistent earnings beats support long-term growth prospects despite current bearish technical signals.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
